Immutep Limited

Biotechnology ResearchNew South Wales, Australia11-50 Employees

Immutep is a late-stage clinical biotechnology company developing novel LAG-3 immunotherapies to fight cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and harness its unique ability to stimulate or suppress the immune response. Our diversified product portfolio includes eftilagimod alpha, a proprietary soluble LAG-3 protein and MHC Class II agonist in oncology, and IMP761, the world's first LAG-3 agonist designed to target the underlying causes of autoimmune diseases. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. 

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Sign up for free to view info

Email Format Employee directory